Adding an Experimental OX40 Drug to Keytruda Nearly Doubled Tumor Responses in Advanced Head and Neck Cancer

An experimental OX40 drug plus Keytruda nearly doubled tumor responses in head and neck cancer. The company’s data are early and not peer-reviewed.

Have A Referral?